Latest Aneuploidy Stories

New research has found that routine screening using a non-invasive test that analyzes fetal DNA in a pregnant woman's blood can accurately detect Down's syndrome and other genetic fetal abnormalities in the first trimester. Published early online in Ultrasound in Obstetrics & Gynecology, the results suggest that the test is superior to currently available screening strategies and could reshape standards in prenatal testing. Current screening for Down's syndrome, or trisomy 21, and...

Brett Smith for redOrbit.com - Your Universe Online By reengineering skin cells from individuals with Down syndrome, scientists at the University of Wisconsin, Madison were able to learn how stem cells develop into dysfunctional brain cells when they contain an extra copy of chromosome 21, the genetic cause of the disorder. "Even though Down syndrome is very common, it's surprising how little we know about what goes wrong in the brain," said Anita Bhattacharyya, a stem cell researcher...

New Innovations to the Harmony Prenatal Test Now Allow for X,Y Analysis and Twin Pregnancies. San Jose, Calif. (PRWEB) May 20, 2013 Ariosa Diagnostics, maker of the non-invasive Harmony™ Prenatal Test for risk assessment of Down syndrome and other chromosome conditions, has announced today the expanded indication for testing of twin pregnancies naturally conceived or conceived using the patient’s own egg. In addition, Ariosa will be offering fetal X,Y analysis as an option to those...

Michael Harper for redOrbit.com – Your Universe Online Multiple studies have concluded high amounts of cholesterol can be damaging to your heart and can, in turn, lead to Alzheimer’s disease or stroke. Though this single fact has been well documented, the exact reason why high cholesterol affects the brain has been largely unclear for many years. Researchers from the Linda Crnic Institute for Down Syndrome and the University of Colorado School of Medicine have studied this link and...

SAN DIEGO, April 16, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that earlier this month, its wholly owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), surpassed 100,000 MaterniT21(TM) PLUS test samples processed since the launch of its laboratory developed test (LDT) in October of 2011. The MaterniT21 PLUS test was the first commercial non-invasive prenatal test...

TROY, Idaho, April 10, 2013 /PRNewswire/ -- In early January, Sabrina Moyer launched a Facebook page (https://www.facebook.com/pages/Special-Miracles-Down-Syndrome/573115916038944) inspired by her son Colton Ryder, who had been diagnosed with Down syndrome soon after his birth in September. The goal was to update family and friends about his growth and development. However, what started out as a personal website quickly turned into a vibrant journey of advocacy attracting thousands...

SAN JOSE, CA, April 6, 2013 /PRNewswire/ - The American College of Medical Genetics (ACMG) issued a position statement to support the use of non-invasive prenatal screening (NIPS) in women with singleton pregnancies. The statement can be found at this link: http://www.acmg.net/docs/nips-GiM_galley_text_130301.pdf (Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO) The statement clearly emphasizes NIPS as a screening, and not diagnostic, test. It goes on to highlight...

SAN JOSE, Calif., March 18, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony(TM) Prenatal Test for risk assessment of common genetic conditions, has announced the expansion of the Harmony Prenatal Test to include the option of Y-chromosome analysis, which can provide information on fetal sex and aneuploidy as early as 10 weeks gestation. (Logo: http://photos.prnewswire.com/prnh/20130225/SF62999LOGO) The new "Harmony with Y test" will offer patients and...

MADISON, N.J. and SAN CARLOS, Calif., Feb. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama(TM), a new non-invasive prenatal test developed by Natera. Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with...

REDWOOD CITY, Calif., Feb. 15, 2013 /PRNewswire/ -- Verinata Health, Inc., a privately-held company dedicated to maternal and fetal health, today presented data demonstrating its approach to detect aneuploidies in maternal blood from multiple gestation pregnancies. (Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO) Contrary to previous study findings by other investigators, this study demonstrated that each fetus in twin pregnancies contributes approximately 50...